UCLB spinout Endomag uses magnetics to remove the need for radioactivity when staging breast cancer. Their technologies, which include Sentimag and Magtrace, have helped create a step-change in breast cancer care.
In 2022, Endomag continued its track record of success, treating its 300,000th patient. Sentimag is now used in over 1,000 hospitals across the world, with one patient being treated every five minutes.
Dr Steven Schooling, Director of Engineering and Physical Sciences at UCLB said, “These statistics illustrate so well the journey that Endomag has been on, and the future growth potential of the company in 2023 and beyond.”